Global B-cell Non Hodgkin Lymphoma Drugs Market 2018-2022: Strong Pipeline, Strategic Alliances & Advanced Technologies - ResearchAndMarkets.com
Sep. 11, 2018
DUBLIN--(BUSINESS WIRE)--Sep 11, 2018--The "Global B-cell Non Hodgkin Lymphoma Drugs Market 2018-2022" report has been added to ResearchAndMarkets.com's offering.
The Global B-Cell Non-Hodgkin Lymphoma Drugs Market to grow at a CAGR of 7.52% during the period 2018-2022.
Global B-cell non-Hodgkin Lymphoma Drugs Market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the Key vendors operating in this market. To calculate the market size, the report considers the revenue generated from the retail sales of B-cell non-Hodgkin lymphoma drugs across the globe.
According to the report, one driver influencing this market is the growing government initiatives. Increasing government initiatives such as Cancer Breakthrough 2020 are driving the growth of the market across the globe. One trend affecting this market is the strong pipeline. The count of pipeline in the B-cell non-Hodgkin lymphoma drugs market is increasing rapidly which is expected to boost the growth of the market.
Further, the report states that one challenge affecting this market is the high cost of treatment. The high cost of treatment is impeding the growth of the global B-cell non-Hodgkin lymphoma drugs market.
Key vendorsBiogen F. Hoffmann-La Roche Merck Novartis Spectrum Pharmaceuticals
Key Topics Covered:
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: MARKET LANDSCAPE
PART 05: MARKET SIZING
PART 06: FIVE FORCES ANALYSIS
PART 07: PIPELINE LANDSCAPE
PART 08: MARKET SEGMENTATION BY CATEGORYComparison by category Small molecules Biologicals Market opportunity by category
PART 09: REGIONAL LANDSCAPEGeographical segmentation Regional comparison Market opportunity
PART 10: CUSTOMER LANDSCAPE
PART 11: DECISION FRAMEWORK
PART 12: DRIVERS AND CHALLENGES
PART 13: MARKET TRENDSStrong pipeline Strategic alliances Advanced technologies
PART 14: VENDOR LANDSCAPE
PART 15: VENDOR ANALYSISVendors covered Vendor classification Market positioning of vendors
For more information about this report visit https://www.researchandmarkets.com/research/g6spcv/global_bcell_non?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180911005681/en/
Laura Wood, Senior Manager
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Lymphoma Drugs
INDUSTRY KEYWORD: HEALTH ONCOLOGY PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 09/11/2018 01:22 PM/DISC: 09/11/2018 01:22 PM